Singularity Capital · Jun 2025
Portfolio write-up summarizing the company’s disease-focused model, founders’ backgrounds, and named investors.
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
San Francisco biotech founded in 2024 that is building multi-modal therapeutics for Rett syndrome and other rare diseases, using a lean, expert-led, capital-efficient approach that combines disease biology, AI, CROs, and existing modality tools to advance preclinical drug candidates.
Primary product
Multi-modal rare-disease therapeutics, starting with Rett syndrome candidates
Founded
2024
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Rare disease therapeutics
Offices
San Francisco, California, United States
Business model
drug discovery and development
preclinical therapeutics
rare-disease biotech
Funding
Stage
seed
Total raised
$500K
Latest round
Seed · Feb 2025
Latest amount
$500K
Feb 2025 · Y Combinator
People & investors
Work & culture
Mission-driven, patient-first, and highly capital-efficient; the company emphasizes deep disease expertise, rapid validation, and a small expert team working with external CROs and advisors.
Product & market
Differentiators
- —Starts with Rett syndrome and plans to expand the same approach to other rare diseases.
- —Uses a polytherapy, multi-modal strategy rather than a single-drug/single-target approach.
- —Focuses on capital-efficient execution with a very small founding team.
- —Leverages mature CROs, AI tools, and expired modality IP to move faster and cheaper.
- —Has already designed multiple therapeutics that were reported to be active in patient cells.
Technology
AI-driven drug discovery
gene editing
antisense oligonucleotides (ASO)
small-molecule therapeutics
CRISPR
mRNA
CAR-T
monoclonal antibodies
contract research organizations (CROs)
Competitors
Acadia Pharmaceuticals
Taysha Gene Therapies
Neurogene
Anavex Life Sciences
Neuren Pharmaceuticals
Scale & contact
Estimated revenue
~$330K estimated annual revenue
Latest news
Hiretop · Apr 2025
Editorial profile on the startup’s mission, Rett syndrome thesis, and early therapeutic candidates.
Y Combinator · Feb 2025
YC launch post highlighting the company’s rare-disease strategy, founder story, and early preclinical therapeutics in patient cell lines.
Startup Intros · Feb 2025
Product launch profile describing the company’s Rett syndrome focus, capital-efficient approach, and early preclinical progress.
Startup Intros · Feb 2025
Reports the company’s $500K seed round and names Y Combinator and Angel Operator Partners as investors.
Jobs and careers at Uncommon Therapeutics
0 jobs at Uncommon Therapeutics
No open positions
Check back later for new openings